{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679277294208.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2336/nishinihonhifu.37.86"}},{"identifier":{"@type":"NDL_BIB_ID","@value":"1587909"}},{"identifier":{"@type":"URI","@value":"http://id.ndl.go.jp/bib/1587909"}},{"identifier":{"@type":"URI","@value":"https://ndlsearch.ndl.go.jp/books/R000000004-I1587909"}},{"identifier":{"@type":"NAID","@value":"130004472268"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/1975098000"}}],"dc:title":[{"@language":"en","@value":"Studies on the Vasoconstrictor Activity of Topical Corticosteroid"},{"@language":"ja","@value":"外用コルチコステロイドの血管収縮作用"},{"@value":"外用コルチコステロイドの血管収縮作用--とくに基剤の影響"},{"@language":"ja-Kana","@value":"ガイヨウ コルチコステロイド ノ ケッカン シュウシュク サヨウ トクニ キザ"}],"dcterms:alternative":[{"@language":"en","@value":"—Especially on the Influence of Vehicles—"},{"@language":"ja","@value":"―とくに基剤の影響―"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"en","@value":"1. In the beginning, a brief description was made on the significance of the vasoconstrictor activity of topical corticosteroids, one of their important biopharmacological effect, and on its correlation with their clinical effectiveness.<BR> 2. The McKenzie-Stoughton method, using the ethanol solution of topical corticosteroid, has been standardized to evaluate the vasoconstrictor activity of each topical corticosteroid. However, as the blanching phenomenon caused by the topical application of corticosteroid is considered to be much influenced by the vehicle used, the author has been comparing and examining the activity with the method using the vehicles currently in use, such as emulsion-type cream, petrolatum etc.<BR> 3. The comparison of the positive frequency in the blanching effect of 0.25% desoximetasone in w/o type cream, 0.12% betamethasone 17-valerate, 0.025% fluocinolone acetonide, 0.1% triamcinolone acetonide, and 0.05% dexamethasone, all being in w/o type cream, under the occlusive dressings for 2, 4 and 20 hours was performed on the flexural aspects of forearms of 24 volunteers. As a result of statistical analysis with the McNemar or binominal test, it was clarified that desoximetasone cream produced the blanching phenomenon significantly easier than other 4 topicums (Table 1-3).<BR> 4. More detailed comparison was made among the vasoconstrictor activity of desoximetasone in w/o cream, betamethasone 17-valerate in o/w cream or petrolatum, and fluocinolone acetonide in o/w cream or petrolatum, with the diluted concentration method. The samples for test, which contained the concentrations of 2<sup>-2</sup> to 2<sup>-12</sup> times as dilute as the commercially available one of each topical corticosteroid in the respective vehicle, were prepared. Thirty test samples were occluded at random on the flexural aspects of forearmss of 8 volunteers for 4 hours. ED<sub>50</sub> (dilution rate ; 95% confidence limits) were calculated and compared among 5 topical drugs. As a result, it was noticed that desoximetasone in creams produced the blanching phenomenon significantly more easily than compared to betamethasone 17-valerate in petrolatum, fluocinolone acetonide in cream or petrolatum, even when the dilution rate of commercially available concentrations was significantly raised. On the other hand, there was no significant differences in the ED<sub>50</sub> (dilution rate ; 95% confidence limits) between desoximetasone in w/o cream and betamethasone 17-valerate in o/w cream (Fig. 2, Table 4). When the ED<sub>50</sub> (concentrations producing blanching effect of each corticosteroid in respective vehicle) were calculated, it was concluded that there were no significant differences among desoximetasone in w/o cream, betamethasone 17-valerate in o/w cream, and fluocinolone acetonide in o/w cream. ED<sub>50</sub> (concentration) of betamethasone 17-valerate in petrolatum was definitely higher when compared with the other 2 topicums, desoximetasone cream and betamethasone 17-valerate cream (Fig. 3, Table 5).<BR> 5. In the author's studies on the influence of vehicles on the blanching phenomenon caused by each topical corticosteroid of the commercially available concentration in the different vehicles, it has been usually observed that emulsion-type creams were most superior, followed by petrolatum, and emulsified lotion, propylene glycol or macrogol were definitely inferior in releasing corticosteroid. Although the more frequent positive reaction of vasoconstriction by each topical corticosteroid in emulsified cream than in petrolatum was usually observed under occlusive dressings for 2 or 4 hours, no differences could be found between them under occluisve dressings for 16 or 20 hours. (to be continuded)"},{"@language":"ja","@value":"1. 2, 4時間密封時, 0.25% desoximetasone(DOM)クリーム(w/o型)は, 0.12% betamethasone valerase(BV), 0.025% fluocinolone acetonide (FA), 0.1% triamcinolone acetonide(TA), 0.05% dexamethasone(D)クリーム(いずれもo/w型)に比し, 血管収縮を生じ易いことを認めた(McNe-mar または2項検定)。<BR> 2. 4時間密封時の血管収縮反応を濃度希釈法により, 比較検討したところ, DOMクリームは, BVクリームとの間には差がないが, FAクリーム, FA軟膏, BV軟膏に比し, 市販濃度の希釈率を有意に大にしても血管収縮が生じやすいことを明らかにした(ED<sub>50</sub> 値, 95% 信頼限界)。なお各コルチコステロイドのED<sub>50</sub>値(濃度)の比較では, DOM, BV, FA各クリーム, FA軟膏間には有意差をみなかつた。<BR> 3. DOMの血管収縮反応の基剤による相違を濃度希釈法により検討したところw/o型, o/w型クリーム, 白色ワセリン間には有意差がなく, マクロゴール軟膏は, クリームに比し有意に劣る成績をえた。"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410009221680062464","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000257929063"}],"foaf:name":[{"@language":"en","@value":"ISHIHARA Masaru"},{"@language":"ja","@value":"石原 勝"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Dermatology, School of Medicine Toho University"},{"@language":"ja","@value":"東邦大学医学部皮膚科教室"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03869784"},{"@type":"LISSN","@value":"03869784"},{"@type":"EISSN","@value":"18804047"},{"@type":"NDL_BIB_ID","@value":"000000017954"},{"@type":"ISSN","@value":"03869784"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/03869784"},{"@type":"NCID","@value":"AN00183881"}],"prism:publicationName":[{"@language":"en","@value":"The Nishinihon Journal of Dermatology"},{"@language":"ja","@value":"西日本皮膚科"},{"@language":"en","@value":"Nishinihon J Dermatol"},{"@language":"en","@value":"Nishi Nihon Hifuka"},{"@language":"ja","@value":"西日皮膚"}],"dc:publisher":[{"@language":"en","@value":"Western Division of Japanese Dermatological Association"},{"@language":"ja","@value":"日本皮膚科学会西部支部"}],"prism:publicationDate":"1975","prism:volume":"37","prism:number":"1","prism:startingPage":"86","prism:endingPage":"95"},"reviewed":"false","url":[{"@id":"http://id.ndl.go.jp/bib/1587909"},{"@id":"https://ndlsearch.ndl.go.jp/books/R000000004-I1587909"},{"@id":"https://search.jamas.or.jp/link/ui/1975098000"}],"availableAt":"1975","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Dermatology","dc:title":"Dermatology"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1362262943646298752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"New type military school"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844242417408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Membership Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204295164160","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Skin vasoconstriction test of methylprednisolone aceponate (SH440) topical preparations. Comparison with commercial preparations of the same category in healthy volunteers."},{"@language":"ja","@value":"Ｍｅｔｈｙｌｐｒｅｄｎｉｓｏｌｏｎｅ　Ａｃｅｐｏｎａｔｅ外用剤（ＳＨ４４０）の皮膚血管収縮試験　健常人における同種同効市販製剤との比較"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204298421888","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effective Application of Topical Corticosteroids"},{"@language":"ja","@value":"ステロイド外用剤の効果的使用"},{"@language":"ja-Kana","@value":"ステロイド ガイヨウザイ ノ コウカテキ シヨウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204298857088","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of Glucocorticoids on DNA Synthesis of Normal Human Skin Fibroblasts in Early Stages of Growth"},{"@language":"ja","@value":"外用グルココルチコイド剤の培養ヒト皮膚線維芽細胞DNA合成におよぼす影響"},{"@value":"Effects of glucocorticoids on DNA synthesis of normal human skin fibroblasts in early stages of growth. In vitro evaluation of anti-proliferative possibly anti-inflammatory potency of glucocorticoids."}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204299107072","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Experimental Evaluation of Delmit Ointments (BV Ointments, 0.06%, 0.12%) and Gels (BV Gels, 0.06%, 0.12%) as Topical Betamethasone Valerate"},{"@language":"ja","@value":"Betamethasone Valerate外用製剤デルミット軟膏, デルミットゲルの抗炎症作用"},{"@value":"Betamethasone Valerate外用製剤デルミット軟膏,デルミットゲルの抗炎症作用--リンデロンV軟膏,リンデロンVクリームとの比較"},{"@language":"ja-Kana","@value":"Betamethasone Valerate ガイヨウ セイザイ デルミット"},{"@value":"吉草酸ベタメタゾン外用製剤デルミット軟こう，デルミットゲルの抗炎症作用　　リンデロンＶ軟こう，リンデロンＶクリームとの比較"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204299140864","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Difluprednate軟膏およびクリームの左右比較試験による臨床効果の検討"},{"@value":"Studies on clinical effect of difluprednate ointment and cream by left-and-right comparison. Comparison with betamethasone 17-valerate by well-controlled comparative study and double blind study."}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204299547520","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Well Controlled Comparative Clinical Study on Halcinonide and Flumethasone Pivalate"},{"@language":"ja","@value":"ハルシノニドクリーム·軟膏とピバル酸フルメタゾンクリーム·軟膏との比較臨床試験"},{"@value":"ハルシノニドクリーム・軟膏とピバル酸フルメタゾンクリーム・軟膏との比較臨床試験"},{"@language":"ja-Kana","@value":"ハルシノニド クリーム ナンコウ ト ピバルサン フルメタゾン クリーム ナン"},{"@value":"ハルシノニドクリーム・軟こうとピバル酸フルメタゾンクリーム・軟こうとの比較臨床試験"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204299649792","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical Trials to Determine the Optimum Concentration of Amcinonide Topical"},{"@language":"ja","@value":"Amcinonide外用剤の至適濃度設定に関する臨床的研究"},{"@language":"ja-Kana","@value":"Amcinonide ガイヨウザイ ノ シテキ ノウド セッテイ ニ カンスル"},{"@value":"アムシノニド外用剤の至適濃度設定に関する臨床的研究"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204300189440","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Quantitative Evaluation of Glucocorticosteroid Permeation in the Stratum Corneum Based on the Sequential Application of Both Glucocorticosteroid Ointment and Moisturizing Ointment"},{"@language":"ja","@value":"ステロイド皮膚外用剤と保湿剤の併用タイミングによるステロイド角層内取り込みへの影響に関する研究"},{"@language":"ja-Kana","@value":"ステロイド ヒフ ガイヨウザイ ト ホシツザイ ノ ヘイヨウ タイミング ニ ヨル ステロイドカクソウ ナイ トリコミ エ ノ エイキョウ ニ カンスル ケンキュウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206127333504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"市販ステロイド外用剤の混合が与えるヒトの血管収縮効果への影響"},{"@language":"en","@value":"Effect of Admixture of Commercially Available Corticosteroid Ointments and/or Creams on Vasoconstrictor Activity"},{"@language":"ja-Kana","@value":"シハン ステロイド ガイヨウザイ ノ コンゴウ ガ アタエル ヒト ノ ケッカン シュウシュク コウカ エ ノ エイキョウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679274511232","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Vasoconstrictive Activity of Budesonide, a New Synthetic Topical Corticosteroid"},{"@language":"ja","@value":"新合成コルチコステロイドBudesonide外用剤の血管収縮能"},{"@language":"ja-Kana","@value":"シン ゴウセイ コルチコステロイド Budesonide ガイヨウザイ ノ ケ"},{"@value":"新合成コルチコステロイドブデソニド外用剤の血管収縮能"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679274781824","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"新外用コルチコステロイド剤Difluprednateの血管収縮能の検討"},{"@value":"Studies on vasoconstricting action of difluprednate, a new external corticosteroid agent. Comparative studies between occlusive dressing therapy and simple inunction therapy."}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679274838016","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of Steroid Ointments on Erythema Induced by UV-Irradiation"},{"@language":"ja","@value":"紫外線紅斑に対するステロイド軟膏の効果"},{"@value":"紫外線紅はんに対するステロイド軟こうの効果"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679275488896","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Chemical Structure and Biological Activity of Topical Corticoids"},{"@language":"ja","@value":"外用コルチコイドの化学構造の生物活性"},{"@value":"外用コルチコイドの化学構造と生物活性"},{"@language":"ja-Kana","@value":"ガイヨウ コルチコイド ノ カガク コウゾウ ト セイブツ カッセイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679276695552","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Double-Blind Controlled Study on the Clinical Efficacy of Topical Corticoids"},{"@language":"ja","@value":"コルチコイド軟膏効果判定における二重盲検法の検討(続報)"},{"@value":"コルチコイド軟膏効果判定における二重盲検法の検討-続-Desoximetasone外用剤の有用性について"},{"@language":"ja-Kana","@value":"コルチコイド ナンコウ コウカ ハンテイ ニ オケル ニジュウ モウケンホウ"},{"@value":"コルチコイド軟こう効果判定における二重盲検法の検討　　デスオキシメタゾン外用剤の有用性"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679277217792","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Studies on the Vasoconstrictor Activity of Amcinonide, a New Synthetic Topical Corticosteroid"},{"@language":"ja","@value":"新合成コルチコステロイドAmcinonide外用剤の血管収縮効果の検討"},{"@language":"ja-Kana","@value":"シン ゴウセイ コルチコステロイド Amcinonide ガイヨウザイ ノ ケ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679277340288","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical and Systemic Effects of Topical Corticosteroid"},{"@language":"ja","@value":"副腎皮質ホルモン外用剤の臨床効果と全身的影響"},{"@value":"副腎皮質ホルモン外用剤の臨床効果と全身的影響--0.1%Halcinonide軟膏およびクリームに関して"},{"@language":"ja-Kana","@value":"フクジン ヒシツ ホルモン ガイヨウザイ ノ リンショウ コウカ ト ゼンシン"},{"@value":"副じん皮質ホルモン外用剤の臨床効果と全身的影響　　０．１％Ｈａｌｃｉｎｏｎｉｄｅ軟こうおよびクリーム"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679277403392","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical Study of Halcinonide on Topical Application"},{"@language":"ja","@value":"Halcinonide外用剤の臨床的検討"},{"@language":"ja-Kana","@value":"Halcinonide ガイヨウザイ ノ リンショウテキ ケントウ"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0029282714"},{"@type":"NDL_SEARCH","@value":"oai:ndlsearch.ndl.go.jp:R000000004-I1587909"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.37.86"},{"@type":"CIA","@value":"130004472268"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.38.286_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.47.1105_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.41.970_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.50.296_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.48.119_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.73.248_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.40.793_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.42.61_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.43.412_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.53.328_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.43.56_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.46.357_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.37.124_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.41.1161_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.43.443_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.41.1149_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"},{"@type":"CROSSREF","@value":"10.1248/yakushi.122.107_references_DOI_VnOKLGvTlBfNaDwqx1pKkIL5PFa"}]}